【摘 要】
：
Background As a rate-limiting enzyme of fatty acid synthesis, acetyl-CoA carhoxylases (ACC) up-regulation has been recognized in multiple human cancers, implicating a critical role in cancer developme
【机 构】
：
Department of Medical Oncology,Changzheng Hospital,Shanghai,People' s Republic of China
【出 处】
：
2014第十届全国癌症康复与姑息医学大会
论文部分内容阅读
Background As a rate-limiting enzyme of fatty acid synthesis, acetyl-CoA carhoxylases (ACC) up-regulation has been recognized in multiple human cancers, implicating a critical role in cancer development and progression, yet its role in gastric cancer still remains unclear.In present study, we detected ACC and pACC expression in gastric cancers and explored its clinical significance.Methods Tissue microarray blocks containing primary gastric cancer and adjacent normal mucosa specimens obtained from 1,072 Chinese patients were used for the detection of ACC and pACC expression by immunohistochemistry.Gastric cancer cell lines were treated by metformin and pACC was measured by Western blotting.Results ACC overexpression was observed in all the tumor specimens.High expression of pACC was found in 630 (58.8%) of the 1,072 primary tumors and in 237 (66.6%) of the 356 primary tumors without lymph node metastasis, Absent/low expression of pACC significantly correlated with advanced T stage, tumor size, lymph node metastasis, advanced disease stage, and poor histological differentiation in 1,072 primary tumors, and with advanced T stage, tumor size, and poor histological differentiation in 356 tumors without lymph node metastasis.Kaplan-meier analysis showed that high expression of pACC is strongly related with better survival rates in all gastric cancer patients.Cox regression analysis revealed that pACC is an independent prognostic factor only in patients without lymph node metastasis.Metformin treatment leaded to increased expression of pACC, which, in turn, resulted in the reduction of cell proliferation and colony formation of gastric cancer cells.Conclusions Increased activation of ACC is frequent in human gastric cancer and downregulation of pACC is an important prognostic factor, suggesting that ACC/pACC might be a potential target for cancer intervention.
其他文献
目的:通过相关症状积分及踝肱比(ABI)或趾肱比(TBI)改善情况随访观察评估糖足煎剂对糖尿病高危足的远期疗效.方法:纳入符合标准的病人66例,随机分为治疗组33例,对照组33例.治疗组给予基础药物加糖足煎剂浴足,对照组给予基础药物加温开水浴足,疗程4周,共3个疗程.停止浴足后随访1年,观察两组临床症状积分及ABI、TBI指标,并进行组内、组间比较.结果:对随访一年的患者症状总积分、血管病变积分、
目的:通过观察糖足煎剂治疗糖尿病高危足相关症状积分及踝/肱比值(ABI)改善的情况,评估其疗效.方法:纳入符合诊断标准的病人64例,采用随机对照研究分为治疗组32例,对照组32例.治疗组给予糖足煎剂浴足,对照组予温开水浴足,分别于治疗3个月后,观察两组临床症状积分及ABI指数.结果:症状总积分比较,治疗组治疗前后有统计学意义(P＜0.05),对照组治疗前后无统计学意义(P＞0.05);ABI比较,
目的:研究补肾法、化痰法、补肾化痰法对BMSCs成骨分化的影响,探讨补肾化痰法治疗骨质疏松症的可能作用机制.方法:运用全骨髓贴壁法分离培养纯化Wsitar大鼠BMSCs,并从细胞形态学、流式细胞仪检测细胞表面抗原等角度进行鉴定.诱导BMSCs成骨分化,观察补肾中药、化痰中药和补肾化痰中药分别对BMSCs成骨分化后茜素红染色及定量、碱性磷酸酶(ALP)活性和骨钙素(OCN) mRNA表达影响.结果:
目的:观察以益气活血、清热化痰为治法组方的甲亢宁对甲亢模型大鼠甲状腺病理结构及超微结构的影响.方法:采用优甲乐灌胃的方法建立甲亢大鼠模型,并分为5组(n=10):模型对照组、PTU对照组、PTU+甲亢宁小、中、大剂量组,另加空白对照组(n=10),分别灌胃.药物干预4周后,观察甲亢宁对甲状腺组织病理结构及超微结构的影响.结果:甲亢宁对甲状腺病理及超微结构有明显的改善作用,而且随着剂量的加大,疗效更
目的:研究人参皂苷Rb1对2型糖尿病记忆障碍小鼠动物学习记忆能力及胰岛素信号通路的影响.方法:雄性10周龄C57BL小鼠16只为正常对照组(N组),雄性10周龄Kkay小鼠64只为模型组,高糖高脂饲料喂养6周后,检测随机血糖≥13.9mmol·L-1后随机分为模型对照组(M组)、阳性对照组(P组)、联合给药高、中、低剂量组(C1、C2、C3组).P组每天用马来酸罗格列酮片按小鼠体重3.0 mg·k
目的:观察四种中药复方对糖尿病大鼠肾小球糖蛋白沉积影响.方法:取链脲霉素诱导的SD大鼠DN模型72只,分成6组,模型对照组、益气养阴方(参芪地黄汤20g·kg-1)组、滋补肝肾方(杞菊地黄汤20g·kg-1)组、补气养血方(当归补血汤20g·kg-1)组、温肾健脾方(附子理中丸20g·kg-1)组和阳性对照(缬沙坦25mg·kg-1)组,每组12只;另取12只大鼠为正常对照组.连续经口灌胃给药8周
笔者在吸取历代医家治疗糖尿病经验的基础上，结合近年现代中医学家的观点，提出糖尿病从肝论治的观点，其目的在于从中医的理论上取得一些突破。文章指出，疏泄、肝主气化是糖尿病发生的关键所在，且病邪伤肝、肝失条达，是糖尿病的基本病机，同时论证了肝与“三消”、“三多”症状的关系，最后作者阐述了中西医结合的最新认识。综上所述，从肝论治糖尿病是最重要的治本之法，如果患者是有典型的“三多一少”症，可配合应用“三消辩
甲状腺囊肿是比较常见的内分泌疾病.西医对它的治疗主要是手术,但手术容易引起并发症,手术有一定的难度,而且容易复发,或者甲状腺全切话需要终身服甲状腺素.这些年来单纯用中药治疗,有比较理的想的疗效,没有发现任何副作用,而且也没有复发的病例.发病原因也不是很明确.它和单纯性甲状腺肿大的缺碘引起是不同的.中医认为情绪致病比较常见.发现这种患者往往情绪暴躁或有过不愉快的经历或求诊时仍然情绪低落，长期肝气郁结
目的：探讨纤维连接蛋白(fibronectin,FN)的表达与骨肉瘤肺转移的关系.方法：回顾性分析36例初发骨肉瘤患者,根据患者术后标准化疗12疗程后随访2年内是否出现肺转移分2组,每组18例,应用SP免疫组化法检测患者骨肉瘤组织病理切片的FN蛋白表达.结果：FN蛋白在转移组阳性率及阳性积分明显高于无转移组,差异有统计学意义(P＜0.05).结论：FN高表达与骨肉瘤肺转移正相关,检测FN蛋白的表达
目的：观察吉西他滨联合替吉奥胶囊三线治疗转移性三阴乳腺癌的近期疗效和毒副反应.方法：吉西他滨1000mg/m2第1天和第8天静脉注射,替吉奥胶囊60mg每日2次口服,连服14天,休息7天,21天为1周期.每例受试者至少进行2个周期治疗进行一次疗效评价.结果：全组41例转移性乳腺癌患者,均为三阴乳腺癌,二线治疗失败,中位年龄55岁,全部随访至死亡.均服药超过2周期,其中CR 0例,PR16例(39.